Stay updated on Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding and updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T10:36:07.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    UI updates include Show glossary and new metadata labels Last Update Submitted that Met QC Criteria and No FEAR Act Data with Revision: v3.4.0. The previous labels Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.
    Difference
    0.2%
    Check dated 2026-01-28T06:31:53.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Footer revision updated to Revision: v3.3.4, replacing v3.3.3; this does not alter trial details or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:32:33.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    A new Locations section includes Baden-Wurttemberg; the Baden-Wurttemberg Locations listing was removed. The HHS Vulnerability Disclosure footer was removed and the page revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T20:19:29.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    Revision tag updated from v3.2.0 to v3.3.2; no substantive study content changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T21:58:53.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    The page no longer displays the government funding and operating status banner. The study details, eligibility criteria, and related trial information remain unchanged.
    Difference
    0.3%
    Check dated 2025-11-17T20:04:27.000Z thumbnail image

Stay in the know with updates to Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial page.